Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusine...
Κύριοι συγγραφείς: | Gidaro, T, Servais, L |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Wiley
2018
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
ανά: Aragon-Gawinska, K, κ.ά.
Έκδοση: (2019) -
Nusinersen and spinal muscular atrophies: Where are we in 2020?
ανά: Satish V Khadilkar, κ.ά.
Έκδοση: (2020-01-01) -
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
ανά: Finkel, RS, κ.ά.
Έκδοση: (2017) -
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
ανά: Tommaso Nuzzo, κ.ά.
Έκδοση: (2023-02-01) -
Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
ανά: Benjamin Stolte, κ.ά.
Έκδοση: (2018-10-01)